Last reviewed · How we verify
NCT06177431
An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease
Phase 1 trial testing Monepantel in Motor Neuron Disease in 12 participants. Completed in 30 May 2025.
30 May 2025
Quick facts
| Lead sponsor | Neurizon Therapeutics Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 13 February 2024 |
| Primary completion | 30 May 2025 |
| Estimated completion | 30 May 2025 |
| Sites | 2 locations across Australia |
Drugs / interventions tested
- Monepantel — full drug profile →
Conditions studied
- Motor Neuron Disease — all drugs for Motor Neuron Disease →
Sponsor
Neurizon Therapeutics Limited
Who can join
Adults 18 to 75, any sex, with Motor Neuron Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, 12-month open label extension study, following Phase 1 Study MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of individuals with MND.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drug repurposing in amyotrophic lateral sclerosis (ALS).
Carroll E, Scaber J, Huber KVM, Brennan PE, et al · · 2025 · cited 3× · PMID 40029669 · DOI 10.1080/17460441.2025.2474661
Verify or expand the search:
- PubMed search for NCT06177431
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Monepantel
Trials testing the same drug.
- NCT04894240 — A Study of Monepantel in Individuals With Motor Neurone Disease · Phase 1 · completed
Other recruiting trials for Motor Neuron Disease
Currently open trials in the same condition.
- NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
- NCT06566651 — Emotion Processing Among Patients With ALS · recruiting
- NCT05744310 — Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families · NA · recruiting
- NCT06318598 — Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis · recruiting
- NCT06318585 — Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases · recruiting
Other Neurizon Therapeutics Limited trials
Trials by the same sponsor.
- NCT04894240 — A Study of Monepantel in Individuals With Motor Neurone Disease · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06177431 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neurizon Therapeutics Limited
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177431.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing